Snapshot
Halozyme Therapeutics, Inc. reported $354M of revenue in Q3 2025, up 22.1% year over year, with diluted EPS of $1.43 and an operating margin of 61.5%.
- Revenue
- $354M
- YoY growth
- +22.1%
- Diluted EPS
- $1.43
- Operating margin
- 61.5%
$354M
Revenue
+22.1%
YoY growth
$1.43
Diluted EPS
61.5%
Operating margin
01 Key takeaways
What management said
- •Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Nicole LaBrosse, our Chief Financial Officer, will review our financial results as well as our outlook.
- •Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
- •I am very pleased to report another quarter of record royalty revenue of $236 million, representing a remarkable 52% increase year-over-year, and resulting in total revenue of $354 million, representing 22% growth year-over-year.
- •Adjusted EBITDA growth exceeded top-line growth, increasing 35% over prior year's third quarter to $248 million, reflecting the strength inherent in our royalty-based business model.
- •Year to date, 13 of the 15 growth catalysts have been achieved, including new product approvals, expanded indications, reaching new regions, and achieving key reimbursement milestones across major markets.
- •This quarter, there were two notable indication approvals for our two leading growth drivers.
- •Firstly, Darzalex Subcutaneous received European Commission approval for a new indication in smoldering multiple myeloma, providing another meaningful growth catalyst for the franchise.
- •Driven by the continued strong performance of our core ENHANZE technology, we are pleased to raise our full year 2025 guidance ranges.
- •Driven by royalty revenues, we now project total revenue of $1.3 billion-$1.375 billion, reflecting 28%-35% growth over 2024.
- •Royalty revenue is now expected to grow 49%-54% to $850 million-$880 million for the full year, primarily driven by our three established blockbuster subcutaneous therapies, Darzalex Subcutaneous, Phesgo, and VYVGART Hytrulo with ENHANZE.
- •We now anticipate adjusted EBITDA of between $885 million and $935 million, representing year-over-year growth of 40%-48%.
- •We expect non-GAAP diluted earnings per share of $6.10-$6.50, representing year-over-year growth of 44%-54%.
SourcesCompany financials · earnings call
Last updated